Key result
A filtration-based time-resolved fluorescence urotensin receptor binding assay demonstrated an improved Z' factor (0.76) and signal-to-background ratio (2.1) compared to a fluorescence polarization assay.
The developed filtration-based TRF assay provides high sensitivity and reproducibility for high-throughput screening of urotensin II receptor antagonists.
May accelerate urotensin II antagonist screening; leaves open clinical translation in cardiovascular disease.
The time-resolved fluorescence (TRF) receptor binding assay has many advantages over the traditional radioligand binding assay in terms of sensitivity and reproducibility for the screening of receptor ligands. The TRF-based urotensin receptor (UT) binding assay with an automatic vacuum filtration system was developed and evaluated for the high-throughput screening of UT receptor antagonists. For this assay development, the human recombinant urotensin II (UII) was modified by labeling europium at its N-terminal position (Eu-UII) and used as a fluorescent tracer. The microsomal membrane fraction of UT receptor was prepared from HEK293 cells stably expressing the human UT receptor. The 50% inhibitory concentration (IC(50)) values of UII from competition binding assays with Eu-UII were 2.76 nM, which is very similar to that of fluorescence polarization (FP)-based UT receptor binding experiment (2.18 nM). Comparing with the FP-based receptor binding assay for UII (Z' factor, 0.36), the current TRF assay presented improved Z' factor (0.76) with a relatively higher signal-to-background ratio (1.5 and 2.1, respectively). The known high-affinity UT receptor antagonists, palosuran and SB657510, exhibited IC(50) values of 23.6 and 73.4 nM, respectively, which were consistent with the IC(50) values from FP-based receptor binding assay (30.6 and 78.7 nM, respectively). These results suggest that our filtration-based TRF UT receptor binding assay can achieve the desired sensitivity with higher reproducibility to adapt for the high-throughput screening of compound libraries.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2011) studied Urotensin II receptor antagonist screening. Time-resolved fluorescence (TRF) receptor binding assay vs. Fluorescence polarization (FP)-based receptor binding assay was evaluated on Z' factor and signal-to-background ratio. A filtration-based time-resolved fluorescence urotensin receptor binding assay demonstrated an improved Z' factor (0.76) and signal-to-background ratio (2.1) compared to a fluorescence polarization assay.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: